Shots:

• Atomwise to receive technology access fees- option exercise fees- royalties- and income-based on sublicensing or sale of assets leading to a total deal value of ~$1.5B. The companies will develop therapies for up to eleven target protein in multiple therapeutic areas
• The agreement involves the collaboration of a scientific team of both the companies- utilizing Atomwise’s AI technology and medicinal chemistry plus protein structure expertise with Hansoh’s research- development & commercialization capabilities
• Atomwise’s technology is the first deep learning AI technology for structure-based small molecule drug discovery. Atomwise collaborated with multiple pharmaceutical & agrochemical companies as well as with Universities & hospital for its AI-based technology across 19 countries

Click here to­ read full press release/ article | Ref: Business Wire | Image: Atomwise